411 related articles for article (PubMed ID: 26237291)
1. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
Maeda H; Tsukigawa K; Fang J
Microcirculation; 2016 Apr; 23(3):173-82. PubMed ID: 26237291
[TBL] [Abstract][Full Text] [Related]
2. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
Nakamura H; Fang J; Maeda H
Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Tumor-Targeted Delivery of Bacteria with Nitroglycerin Involving Augmentation of the EPR Effect.
Fang J; Long L; Maeda H
Methods Mol Biol; 2016; 1409():9-23. PubMed ID: 26846798
[TBL] [Abstract][Full Text] [Related]
4. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K
J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
[TBL] [Abstract][Full Text] [Related]
5. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.
Maeda H
Bioconjug Chem; 2010 May; 21(5):797-802. PubMed ID: 20397686
[TBL] [Abstract][Full Text] [Related]
6. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
Fang J; Sawa T; Maeda H
Adv Exp Med Biol; 2003; 519():29-49. PubMed ID: 12675206
[TBL] [Abstract][Full Text] [Related]
7. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers.
Fang J; Islam W; Maeda H
Adv Drug Deliv Rev; 2020; 157():142-160. PubMed ID: 32553783
[TBL] [Abstract][Full Text] [Related]
8. Styrene-maleic acid-copolymer conjugated zinc protoporphyrin as a candidate drug for tumor-targeted therapy and imaging.
Fang J; Tsukigawa K; Liao L; Yin H; Eguchi K; Maeda H
J Drug Target; 2016; 24(5):399-407. PubMed ID: 26302870
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors.
Islam R; Maeda H; Fang J
Expert Opin Drug Deliv; 2022 Feb; 19(2):199-212. PubMed ID: 33430661
[TBL] [Abstract][Full Text] [Related]
10. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
11. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.
Maeda H; Nakamura H; Fang J
Adv Drug Deliv Rev; 2013 Jan; 65(1):71-9. PubMed ID: 23088862
[TBL] [Abstract][Full Text] [Related]
12. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
Greish K
Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
[TBL] [Abstract][Full Text] [Related]
13. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications.
Maeda H; Fang J; Inutsuka T; Kitamoto Y
Int Immunopharmacol; 2003 Mar; 3(3):319-28. PubMed ID: 12639809
[TBL] [Abstract][Full Text] [Related]
14. Polymer therapeutics and the EPR effect.
Maeda H
J Drug Target; 2017; 25(9-10):781-785. PubMed ID: 28988499
[TBL] [Abstract][Full Text] [Related]
15. N-(2-hydroxypropyl)methacrylamide polymer conjugated pyropheophorbide-a, a promising tumor-targeted theranostic probe for photodynamic therapy and imaging.
Fang J; Šubr V; Islam W; Hackbarth S; Islam R; Etrych T; Ulbrich K; Maeda H
Eur J Pharm Biopharm; 2018 Sep; 130():165-176. PubMed ID: 29885851
[TBL] [Abstract][Full Text] [Related]
16. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
Islam W; Fang J; Imamura T; Etrych T; Subr V; Ulbrich K; Maeda H
Mol Cancer Ther; 2018 Dec; 17(12):2643-2653. PubMed ID: 30232144
[TBL] [Abstract][Full Text] [Related]
18. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.
Maeda H
Adv Drug Deliv Rev; 2015 Aug; 91():3-6. PubMed ID: 25579058
[TBL] [Abstract][Full Text] [Related]
19. The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives.
Sun R; Xiang J; Zhou Q; Piao Y; Tang J; Shao S; Zhou Z; Bae YH; Shen Y
Adv Drug Deliv Rev; 2022 Dec; 191():114614. PubMed ID: 36347432
[TBL] [Abstract][Full Text] [Related]
20. Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection.
Natfji AA; Ravishankar D; Osborn HMI; Greco F
J Pharm Sci; 2017 Nov; 106(11):3179-3187. PubMed ID: 28669714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
